Ladenburg Thalmann analyst Matthew Kaplan downgraded Dova Pharmaceuticals Inc (NASDAQ: DOVA) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst PT Change Downgrades

JPMorgan Upgrades Dova Pharmaceuticals Inc (DOVA) to Neutral Following AcquisitionOctober 3, 2019 4:22 AM Form 4 Dova Pharmaceuticals For: Oct 01 Filed by: ZACCARDELLI DAVIDOctober 2, 2019 4:21 PM Form 4 Dova Pharmaceuticals For: Sep 30 Filed by: ALLEN LEE F MD PhDOctober 2, 2019 4:21 PM Form 4 Dova Pharmaceuticals For: Sep 30 Filed by: Hahn Mark WOctober 2, 2019 4:21 PM Form 4 Dova Pharmaceuticals For: Sep 30 Filed by: Hoitt JasonOctober 2, 2019 4:21 PM Form 4 Dova Pharmaceuticals For: Sep 30 Filed by: Laliberte KevinOctober 2, 2019 4:21 PM Form SC TO-C Dova Pharmaceuticals Filed by: Swedish Orphan Biovitrum AB (publ)October 1, 2019 5:13 PM UniCredit to sell 5 billion euros of soured home mortgages next month: sourcesOctober 1, 2019 12:00 PM